TP53 and acute myeloid leukemia: To extend this analysis, we used nanoranger to genotype individual AML/MDS cells originating from 9 patients enrolled in either of the two cohorts, targeting 11 recurrently mutated AML/MDS-associated genes (ASXL1, DNMT3A, NRAS, IDH2, RUNX1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1) (Supplementary Table 4).